Device Trial Radar · NCT03232333
MIRODERM H2H DFU Study
Last checked: Nov 20, 2026Latest source record: Oct 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jul 21, 2017
Primary completion
Sep 20, 2018
Study completion Sep 20, 2018
Sponsor
- Lead sponsor
- Miromatrix Medical Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 28, 2017
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.
Conditions
- Diabetic Foot Ulcer
Interventions
Biologic wound graftDevice
Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of ParticipantsTime frame: 12 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
ILD Research
Carlsbad, California
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.